111 related articles for article (PubMed ID: 10739956)
1. Substrate specificity of bovine cathepsin B and its inhibition by CA074, based on crystal structure refinement of the complex.
Yamamoto A; Tomoo K; Hara T; Murata M; Kitamura K; Ishida T
J Biochem; 2000 Apr; 127(4):635-43. PubMed ID: 10739956
[TBL] [Abstract][Full Text] [Related]
2. Binding mode of CA074, a specific irreversible inhibitor, to bovine cathepsin B as determined by X-ray crystal analysis of the complex.
Yamamoto A; Hara T; Tomoo K; Ishida T; Fujii T; Hata Y; Murata M; Kitamura K
J Biochem; 1997 May; 121(5):974-7. PubMed ID: 9192742
[TBL] [Abstract][Full Text] [Related]
3. Molecular dynamics simulations of bovine cathepsin B and its complex with CA074.
Yamamoto A; Tomoo K; Miyagawa H; Takaoka Y; Sumiya S; Kitamura K; Ishida T
Chem Pharm Bull (Tokyo); 2000 Apr; 48(4):480-5. PubMed ID: 10783065
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for development of cathepsin B-specific noncovalent-type inhibitor: crystal structure of cathepsin B-E64c complex.
Yamamoto A; Tomoo K; Matsugi K; Hara T; In Y; Murata M; Kitamura K; Ishida T
Biochim Biophys Acta; 2002 Jun; 1597(2):244-51. PubMed ID: 12044902
[TBL] [Abstract][Full Text] [Related]
5. X-ray crystal structure of papain complexed with cathepsin B-specific covalent-type inhibitor: substrate specificity and inhibitory activity.
Matsumoto K; Murata M; Sumiya S; Mizoue K; Kitamura K; Ishida T
Biochim Biophys Acta; 1998 Mar; 1383(1):93-100. PubMed ID: 9546050
[TBL] [Abstract][Full Text] [Related]
6. Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.
Watanabe D; Yamamoto A; Tomoo K; Matsumoto K; Murata M; Kitamura K; Ishida T
J Mol Biol; 2006 Oct; 362(5):979-93. PubMed ID: 16950396
[TBL] [Abstract][Full Text] [Related]
7. The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity.
Musil D; Zucic D; Turk D; Engh RA; Mayr I; Huber R; Popovic T; Turk V; Towatari T; Katunuma N
EMBO J; 1991 Sep; 10(9):2321-30. PubMed ID: 1868826
[TBL] [Abstract][Full Text] [Related]
8. Molecular design of potent inhibitor specific for cathepsin B based on the tertiary structure prediction.
Sumiya S; Yoneda T; Kitamura K; Murata M; Yokoo C; Tamai M; Yamamoto A; Inoue M; Ishida T
Chem Pharm Bull (Tokyo); 1992 Feb; 40(2):299-303. PubMed ID: 1606628
[TBL] [Abstract][Full Text] [Related]
9. Use of papain as a model for the structure-based design of cathepsin K inhibitors: crystal structures of two papain-inhibitor complexes demonstrate binding to S'-subsites.
LaLonde JM; Zhao B; Smith WW; Janson CA; DesJarlais RL; Tomaszek TA; Carr TJ; Thompson SK; Oh HJ; Yamashita DS; Veber DF; Abdel-Meguid SS
J Med Chem; 1998 Nov; 41(23):4567-76. PubMed ID: 9804696
[TBL] [Abstract][Full Text] [Related]
10. The binding mode of an E-64 analog to the active site of cathepsin B.
Feng MH; Chan SL; Xiang Y; Huber CP; Lim C
Protein Eng; 1996 Nov; 9(11):977-86. PubMed ID: 8961350
[TBL] [Abstract][Full Text] [Related]
11. Inhibition mechanism of cathepsin L-specific inhibitors based on the crystal structure of papain-CLIK148 complex.
Tsuge H; Nishimura T; Tada Y; Asao T; Turk D; Turk V; Katunuma N
Biochem Biophys Res Commun; 1999 Dec; 266(2):411-6. PubMed ID: 10600517
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of the parasite inhibitor chagasin in complex with papain allows identification of structural requirements for broad reactivity and specificity determinants for target proteases.
Redzynia I; Ljunggren A; Bujacz A; Abrahamson M; Jaskolski M; Bujacz G
FEBS J; 2009 Feb; 276(3):793-806. PubMed ID: 19143838
[TBL] [Abstract][Full Text] [Related]
13. S-S bridges of cathepsin B and H from bovine spleen: a basis for cathepsin B model building and possible functional implications for discrimination between exo- and endopeptidase activities among cathepsins B, H and L.
Baudys M; Meloun B; Gan-Erdene T; Fusek M; Mares M; Kostka V; Pohl J; Blake CC
Biomed Biochim Acta; 1991; 50(4-6):569-77. PubMed ID: 1801725
[TBL] [Abstract][Full Text] [Related]
14. pH Dependence of inhibitors targeting the occluding loop of cathepsin B.
Cathers BE; Barrett C; Palmer JT; Rydzewski RM
Bioorg Chem; 2002 Aug; 30(4):264-75. PubMed ID: 12392705
[TBL] [Abstract][Full Text] [Related]
15. Structural basis of inhibition of cysteine proteases by E-64 and its derivatives.
Matsumoto K; Mizoue K; Kitamura K; Tse WC; Huber CP; Ishida T
Biopolymers; 1999; 51(1):99-107. PubMed ID: 10380357
[TBL] [Abstract][Full Text] [Related]
16. Crystal structures of recombinant rat cathepsin B and a cathepsin B-inhibitor complex. Implications for structure-based inhibitor design.
Jia Z; Hasnain S; Hirama T; Lee X; Mort JS; To R; Huber CP
J Biol Chem; 1995 Mar; 270(10):5527-33. PubMed ID: 7890671
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of NS-134 in complex with bovine cathepsin B: a two-headed epoxysuccinyl inhibitor extends along the entire active-site cleft.
Stern I; Schaschke N; Moroder L; Turk D
Biochem J; 2004 Jul; 381(Pt 2):511-7. PubMed ID: 15084146
[TBL] [Abstract][Full Text] [Related]
18. Crystal structure of the wild-type human procathepsin B at 2.5 A resolution reveals the native active site of a papain-like cysteine protease zymogen.
Podobnik M; Kuhelj R; Turk V; Turk D
J Mol Biol; 1997 Sep; 271(5):774-88. PubMed ID: 9299326
[TBL] [Abstract][Full Text] [Related]
19. Role of the single cysteine residue, Cys 3, of human and bovine cystatin B (stefin B) in the inhibition of cysteine proteinases.
Pol E; Björk I
Protein Sci; 2001 Sep; 10(9):1729-38. PubMed ID: 11514663
[TBL] [Abstract][Full Text] [Related]
20. Crystallization and preliminary X-ray study of the cathepsin B complexed with CA074, a selective inhibitor.
Yamamoto A; Kaji T; Tomoo K; Ishida T; Inoue M; Murata M; Kitamura K
J Mol Biol; 1992 Oct; 227(3):942-4. PubMed ID: 1404397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
